Goldman Sachs stock slides into weekend after CEO pay hits $47 million — what to watch next
24 January 2026
2 mins read

Goldman Sachs stock slides into weekend after CEO pay hits $47 million — what to watch next

New York, Jan 24, 2026, 05:50 EST — Market closed.

  • Goldman Sachs shares dropped 3.75% on Friday, ending the day at $918.88 following a volatile session with swings exceeding $20.
  • A regulatory filing revealed CEO David Solomon’s compensation for 2025 climbed to $47 million, driven largely by stock awards.
  • Investors are entering Monday with a sharp eye on policy risks and the upcoming earnings reports that could validate current market valuations.

Shares of Goldman Sachs Group Inc fell 3.75% to close at $918.88 on Friday, with intraday swings between $917.05 and $937.19. After-hours trading saw little movement, keeping the stock flat.

The decline is significant since Goldman serves as a key Wall Street indicator, with its shifts often influencing broader sentiment around dealmaking and market liquidity.

This comes just before a busy week packed with catalysts, a period when traders often crack down on anything that seems like “too much” — whether that’s pricing, risk, or optimism — particularly in financial stocks.

The Dow slipped 0.58% on Friday, while the S&P 500 barely moved, dragged down by Intel’s 17% plunge after a grim forecast, Reuters reports. “We feel pretty good about where we are today,” said Jason Blackwell, chief investment strategist at Focus Partners Wealth. Julian McManus, portfolio manager at Janus Henderson, described the market as entering a “show-me” phase. Investing.com

Goldman revealed in a Form 8-K that its board pegged CEO David Solomon’s 2025 compensation at $47 million, rising from $39 million the previous year. The breakdown: $2 million salary and $45 million in variable pay. This includes $31.5 million in performance share units tied to firmwide goals, $10.1 million in cash, and $3.4 million linked to a carried-interest program. The committee pointed to a 57% total shareholder return in 2025, combining share gains and dividends. They also noted the firm reported $58.28 billion in net revenue, $17.18 billion in net earnings, and a 15% return on equity.

Solomon’s pay package outstripped JPMorgan Chase CEO Jamie Dimon’s $43 million reported just a day before, Reuters noted. Goldman also appointed President and COO John Waldron to its board, signaling him as a likely successor, the outlet added. Goldman’s stock climbed 53.5% in 2025, according to Reuters.

Goldman Sachs raised its gold price target for the end of 2026 to $5,400 an ounce, up from $4,900. The bank pointed to private investors and central banks in emerging markets shifting their portfolios toward bullion.

Goldman investors are now watching to see if volatility will sustain market activity or bring underwriting and merger talks to a halt. Friday’s sharp intraday swings highlighted just how fast risk appetite can shift.

Yet the setup works both ways. A sudden jump in bond yields or fresh trade-related turmoil could drag down equities and client activity simultaneously — a tough scenario for any investment bank.

The Federal Reserve’s two-day meeting on Jan. 27-28 is the next major event on the calendar. The Fed has scheduled its announcement for 2:00 p.m. on Jan. 28, followed by a press conference at 2:30 p.m. U.S. markets will reopen Monday, Jan. 26, with investors closely monitoring whether bank stocks continue to slide after Friday’s selloff.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Revolution Medicines (RVMD) Shares Trade at a Premium Despite Robust Gains
    July 25, 2026, 2:47 PM EDT. Revolution Medicines (RVMD) shares have jumped with a 399.2% return over the past year and approximately 6.4x growth in three years, though the stock's valuation is considered steep. With a P/B ratio of 26.8x, Revolution Medicines is well above the Biotech sector's 2.5x average and peer level of 10.3x. The stock meets just 2 out of 6 valuation criteria, indicating a premium linked to its FDA-reviewed drug daraxonrasib and data from its pancreatic cancer trial, along with concerns tied to regulatory risk.
British American Tobacco share price in focus before London open after buyback disclosure
Previous Story

British American Tobacco share price in focus before London open after buyback disclosure

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Next Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week